Studies from China Pharmaceutical University in the Area of Gliomas Reported [Lactoferrin-Modified Poly(ethylene glycol)-Grafted BSA Nanoparticles as a Dual-Targeting Carrier for Treating Brain Gliomas]
By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Oncology have been presented. According to news reporting from Jiangsu, People's Republic of China, by NewsRx journalists, research stated, "In this study, a dual-targeting drug delivery system based on bovine serum albumin nanoparticles (BSA-NPs) modified with both lactoferrin (Lf) and mPEG2000 loading doxorubicin (DOX) was designed, and its blood-brain barrier (BBB) penetration and brain glioma cells targeting properties were explored. BSA-NPs were prepared by a desolvation technique, and mPEG2000 was incorporated onto the surface of BSA-NPs by reacting with the free amino-group of BSA to form mPEG2000-modified BSA-NPs (P-2000-NPs)."
The news correspondents obtained a quote from the research from China Pharmaceutical University, "Finally, Lf-modified P(2000-)NPs (Lf-NPs) was obtained by absorbing Lf onto the surface of P-2000-NPs via the positive and negative charges interaction at physiological pH. Three levels of mPEG2000 and Lf-modified NPs were prepared and characterized, respectively. The uptake and potential cytotoxicity of different DOX preparations in vitro by the primary brain capillary endothelial cells (BCECs) and glioma cells (C6) were investigated. The dual-targeting effects were studied on the BBB model in vitro, BCECs/C6 glioma coculture model in vitro, and C6 glioma-bearing rats in vivo, respectively. The results exhibited that, with the increase of the amount of both mPEG2000 and Lf, the particle size of NPs increased and its zeta potential decreased. The in vivo pharmacokinetics study in healthy rats exhibited that P-2000-NPs with a high level of mPEG2000 (P-2000H-NPs) had longer circulation time in vivo. Compared to other NPs, Lf-NPs with high level of both Lf and mPEG2000 (Lf(H)-NPs) showed the strongest cytotoxicity and the highest effectiveness in the uptake both in BCECs and C6 as well as improved the dual-targeting effects. Body distribution of DOX in different formulations revealed that Lf(H)-NPs could significantly increase the accumulation of DOX in the brain, especially at 2 h postinjection (P < 0.05)."
According to the news reporters, the research concluded: "Lf-NPs were a prospective dual-targeting drug delivery system for effective targeting therapy of brain gliomas."
For more information on this research see: Lactoferrin-Modified Poly(ethylene glycol)-Grafted BSA Nanoparticles as a Dual-Targeting Carrier for Treating Brain Gliomas. Molecular Pharmaceutics, 2014;11(6):1823-1834. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
Our news journalists report that additional information may be obtained by contacting Z.G. Su, China Pharmaceutical University, State Key Lab Nat Med, Dept. of Pharmaceut, Nanjing 210009, Jiangsu, People's Republic of China. Additional authors for this research include L. Xing, Y.N. Chen, Y.R. Xu, F.F. Yang, C. Zhang, Q.N. Ping and Y.Y. Xiao (see also Oncology).
Keywords for this news article include: Asia, Glioma, Jiangsu, Oncology, Lactoferrin, Nanoparticle, Glycoproteins, Lactoglobulins, Nanotechnology, Dietary Proteins, Emerging Technologies, Iron-Binding Proteins, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC